Global Controlled Release Drug Delivery Market, Drug Dosage, Price, Sales & Clinical Trials Insight 2030

List of Tables

Global Controlled Release Drug Delivery Market, Drug Dosage, Price, Sales & Clinical Trials Insight 2030 Report Finding & Highlights:

Research Methodology
Global & Regional Market Overview
Global Market Size Insight In US$ Billion: 2022 - 2030
Global Market Opportunity: > US$ 90 Billion
Insight On Controlled Release Drugs In Clinical Trials: > 190 Drugs
Global Controlled Release Drugs Clinical Pipeline By Company, Indication & Phase
Insight On Approved & Marketed Controlled Release Drugs: > 180 Drugs
Controlled Release Drugs Dosage, Pricing & Sales Insight
Competitive Landscape

Need for Controlled Drug Release Systems & Why This Report?

The demand for controlled drug release systems has increased as both healthcare practitioners and patients seek improved, more convenient, and safer therapeutic regimens. Chronic diseases like diabetes, cardiovascular diseases, and neurological disorders call for long-term therapy, and the limitations associated with conventional dosing, such as repeated administration and variable drug absorption, frequently undermine treatment efficacy. Controlled drug release systems resolve these issues by maintaining uniform levels of drugs for a prolonged duration, minimizing the frequency of dosing, and improving the therapeutic efficacy. Controlled drug release systems also assist in the reduction of side effects, patient compliance, and the optimization of the pharmacokinetics of drugs.

This report gives an in-depth look at the changing landscape of drug controlled release technologies, underlining the innovations, clinical trends, and key market players. With the demand for improved drug delivery increasing, this analysis is an eye opener to future growth and opportunities in this growing market. Apart from the latest technological developments and emerging trends, it also contains in-depth pricing data for more than 60 medicines, as well as sales performance data for specific products. This blend of strategic recommendations and market data is meant to guide industry participants, enabling them to make informed decisions in drug development, delivery, and commercialization.

Clinical Trials Insight Included In Report

Clinical trials are crucial in validating the efficacy and safety of drug delivery systems with controlled release. There are detailed insights into several key clinical trials in this report, and giving a preview of the development in the area. The information provided in this section specifically comprises stages of trials, sponsors, geographical distribution, technology providers, collaborators and license holders. The trials cover a variety of therapeutic categories, including pain management and oncology to neurological diseases and metabolic disorders.

Major Companies Active In R&D of Controlled Drug Release Systems

A number of major pharmaceutical and biotech firms are currently engaged in the development of controlled drug release systems. These firms are leaders in R&D activities, employing advanced technologies to develop more efficient and patient-friendly medicines. The report identifies prominent players like AbbVie, AstraZeneca, and Merck, which are looking for novel drug delivery platforms to enhance the treatment of chronic diseases as well as conditions like cancer, neurological disorders, and metabolic disorders.

Along with major pharmaceutical firms, smaller startups are also taking lead in creating new controlled release systems. Firms such as SpyGlass Pharma and Glaukos Corporation are pushing the boundaries of controlled-release platforms in ophthalmology, whereas partnerships like that of Boehringer Ingelheim with Re-Vana Therapeutics are developing biodegradable implants for retinal illnesses. The report also explains how these collaborations are spurring the commercialization of new-generation drug delivery systems.

Report Indicating Future Direction Of Controlled Drug Release Systems Segment

The future for controlled drug release systems promises significant growth and development. According to the report, the emphasis will be placed on the use of more personalized and targeted drug delivery mechanisms, sparked by developments in biotechnology and digital health technologies. The advent of precision medicine will propel the creation of customized drug release systems that respond to each patient's requirements, even further enhancing the effectiveness of treatment and patients' compliance.

Moreover, our research anticipates a wider use of non-invasive drug delivery techniques, including implantable systems and transdermal patches, as they are convenient and cause less discomfort to patients. Increasing applications in neurodegenerative disorders, personalized oncology, and rare diseases will also propel the market forward.

As investment in R&D continues and regulatory backing for innovative drug delivery technologies is further enhanced, controlled drug release system market growth will persist, presenting substantial opportunities for firms developing such sophisticated therapies.

1. Introduction To Controlled Drug Delivery

1.1 Fundamentals & Technology
1.2 Classification By System, Route & Technology
1.3 Mechanisms Of Action

2. Material Based Approaches For Controlled Drug Delivery

2.1 Polymers
2.2 Chronopharmaceutics
2.3 Nanoparticulate Delivery System

3. Global Controlled Release Drug Delivery Market Trends

3.1 Current Market Scenario
3.2 Future Market Outlook

4. Controlled Drug Delivery Research & Clinical Trends By Indication

4.1 Neurological Disorders
4.2 Cardiovascular Diseases
4.3 Diabetes
4.4 Cancer
4.5 Microbial Infections

5. Global Controlled Release Drug Market Trends By Region

5.1 US
5.2 Europe
5.3 Japan
5.4 China
5.5 Canada
5.6 South Korea

6. Global Controlled Release Drugs Clinical Pipeline By Company, Indication & Phase

6.1 Research
6.2 Preclinical
6.3 Phase-I
6.4 Phase-I/II
6.5 Phase-II
6.6 Phase-II/III
6.7 Phase-III
6.8 Preregistration
6.9 Registered

7. Marketed Controlled Release Drugs Clinical Insight By Company, Country & Indication

8. Controlled Release Drugs for Alzheimer's Disease - Pricing & Dosage Insight

8.1 Namzaric (Extended-Release)
8.2 Namenda XR (Extended-Release)
8.3 Razadyne ER (Extended Release)

9. Controlled Release Drugs for Parkinson's Disease - Pricing & Dosage Insight

9.1 Gocovri (Extended-Release)
9.2 Osmolex ER (Extended-Release)
9.3 Mirapex ER (Extended-Release)

10. Controlled Release Drugs for Schizophrenia - Pricing & Dosage Insight

10.1 Invega (Extended-Release)
10.2 Invega Franchise/Invega Hafyera (Extended-Release)
10.3 Seroquel XR (Extended-Release)
10.4 Abilify Franchise (Extended-Release)
10.5 Aristada/Aristada Initio (Extended-Release)
10.6 Rykindo (Extended-Release)
10.7 Risperdal Consta (Extended-Release)
10.8 Uzedy (Extended-Release)

11. Controlled Release Drugs for Chronic & Post-Operative Pain - Pricing & Dosage Insight

11.1 Hysingla ER (Extended-Release)
11.2 Nucynta ER (Extended-Release)
11.3 Kadian (Extended-Release)
11.4 Xtampza ER (Extended-Release)
11.5 MS Contin (Extended-Release)
11.6 Embeda (Extended-Release)
11.7 Posimir (Sustained-Release)
11.8 Zynrelef (Extended-Release)
11.9 ConZip (Extended-Release)
11.10 Generic Hydromorphone (Extended-Release)

12. Controlled Release Drugs for Multiple Sclerosis - Pricing & Dosage Insight

12.1 Ampyra / Fampyra (Extended-Release)
12.2 Tecfidera (Delayed-Release)
12.3 Vumerity (Delayed-Release)
12.4 Rayos (Delayed-Release)
12.5 Bafiertam (Delayed-Release)

13. Controlled Release Drugs for Diabetes Mellitus Type II - Pricing & Dosage Insight

13.1 Glumetza (Extended-Release)
13.2 Glucotrol XL (Extended-Release)
13.3 Glucophage XR (Extended-Release)
13.4 Trijardy XR (Extended-Release)
13.5 Synjardy XR (Extended-Release)

14. Controlled Release Drugs for Cardiovascular Diseases - Pricing & Dosage Insight

14.1 Procardia XL (Extended-Release)
14.2 Toprol XL (Extended-Release)
14.3 Verelan PM (Extended-Release)
14.4 Cardizem LA (Extended-Release)
14.5 Calan SR (Sustained-Release)
14.6 Altoprev (Extended-Release)
14.7 Cardura XL (Extended-Release)

15. Controlled Release Drugs for HIV - Pricing & Dosage Insight

15.1 Apretude (Extended-Release)
15.2 Cabenuva (Extended-Release)
15.3 Rukobia (Extended-Release)

16. Controlled Release Drugs for Attention Deficit Hyperactivity Disorder - Pricing & Dosage Insight

16.1 Qelbree (extended-release)
16.2 Jornay PM (Extended-Release)
16.3 Cotempla XR-ODT (Extended-Release)
16.4 Adzenys XR-ODT (Extended-Release)
16.5 Intuniv (Extended-Release)
16.6 Focalin XR (Extended-Release)

17. Controlled Release Drugs for Inflammatory & Autoimmune Diseases - Pricing & Dosage Insight

17.1 Rinvoq (Extended-Release)
17.2 Ortikos (Extended-Release)
17.3 Xeljanz XR (Extended-Release)
17.4 Mestinon Timespan (Extended-Release)
17.5 Symax Duotab (Extended-Release)

18. Controlled Release Drugs for Bacterial Infections - Pricing & Dosage Insight

18.1 Aemcolo (Delayed-Release)
18.2 Talicia (Delayed-Release)

19. Controlled Release Drugs for Opioid Use Disorder - Pricing & Dosage Insight

19.1 Sublocade (Sustained-Release)
19.2 Brixadi (Extended-Release)

20. Controlled Release Drugs for Preventing Organ Transplant Rejection - Pricing & Dosage Insight

20.1 Astagraf XL (Extended-Release)
20.2 Envarsus XR (Extended-Release)

21. Controlled Release Drugs for Migraine & Seizure - Pricing & Dosage Insight

21.1 Trokendi XR (Extended-Release)
21.2 Oxtellar XR (Extended-Release)
21.3 Keppra XR (Extended-Release)
21.4 Roweepra XR (Extended-Release)
21.5 Depakote, Depakote ER, & Depakote Sprinkles

22. Controlled Release Drugs for Mental Health and Sleep Disorders - Pricing & Dosage Insight

22.1 Effexor XR (Extended-Release)
22.2 Xanax XR (Extended-Release)
22.3 Ambien CR (Extended-Release)

23. Controlled Release Drugs for Metabolic and Electrolyte Disorders - Pricing & Dosage Insight

23.1 Klor-Con 8, Klor-Con 10, Klor-Con M10, Klor-Con M15, Klor-Con M20

24. Global Controlled Drug Delivery System Market Dynamics

24.1 Market Drivers & Opportunities
24.2 Market Challenges & Restraints

25. Competitive Landscape

25.1 AbbVie
25.2 Antlia Bioscience
25.3 Arbor Pharmaceuticals (Azurity Pharmaceuticals)
25.4 AstraZeneca
25.5 Bausch Health Companies
25.6 Biodexa Pharmaceuticals
25.7 Boehringer Ingelheim
25.8 Camurus
25.9 DURECT Corporation
25.10 Emplicure
25.11 HLK Pharmacin
25.12 Jemincare
25.13 Johnson & Johnson
25.14 Luye Pharma Group
25.15 Lyndra
25.16 Mallinckrodt plc
25.17 MedinCell S.A.
25.18 Merck
25.19 Otsuka Pharmaceutical
25.20 Pacira BioSciences
25.21 Pfizer
25.22 Purdue Pharma
25.23 Roche
25.24 Sanofi
25.25 Serina Therapeutics
25.26 Sun Pharmaceutical Industries
25.27 Supernus Pharmaceuticals
25.28 Takeda
25.29 Tris Pharma
25.30 ViiV Healthcare

List of Figures

Figure 1-1: Conventional Drug Delivery Systems - Limitations
Figure 1-2: Novel Drug Delivery Platform Diversification
Figure 1-3: Evolution Of Drug Delivery Technology: 1st to 3rd Generation
Figure 1-4: Challenges Addressed By Third Generation Drug Delivery
Figure 1-5: Targeted vs. Non-Targeted Drug Delivery
Figure 1-6: Zero-Order Controlled Drug Release
Figure 1-7: Plasma Concentration-Time Profile: Conventional vs. Controlled Release
Figure 1-8: Comparison Of Modified Drug Release Systems
Figure 1-9: Pulsatile Drug Release Mechanism In Pulsincap
Figure 1-10: Classification By Technical Complexity
Figure 1-11: Structural Differences Among Drug Delivery Systems
Figure 1-12: Classification By Route of Administration
Figure 1-13: Types Of Diffusion-Controlled Mechanisms
Figure 1-14: Encapsulation Dissolution-Controlled Mechanism
Figure 1-15: Osmotic Controlled Drug Release
Figure 1-16: Erosion Mechanisms In Matrix Systems
Figure 2-1: Polymeric Controlled Drug Delivery Devices - Categories
Figure 2-2: Nanostructures For Nanoparticulate Delivery Systems
Figure 3-1: Global - Controlled Release Drug Delivery Market Size (US$ Billion), 2022 - 2025
Figure 3-2: Global - Controlled Release Drug Delivery Market Forecast (US$ Billion), 2026 - 2030
Figure 4-1: Major Non-Invasive Routes For Insulin Delivery
Figure 4-2: Controlled Drug Delivery Strategies In Cancer Therapy
Figure 6-1: Global - Controlled Release Drug Clinical Pipeline By Phase (Number), 2025 Till 2030
Figure 8-1: Namzaric - Price Per Unit & Supply (US$), August'2025
Figure 8-2: Generic Donepezil/Memantine - Price Per Unit & Supply (US$), August'2025
Figure 8-3: Namenda XR - Price Per Unit & Supply Of 7mg & 21mg Extended Release Capsules (US$), August'2025
Figure 8-4: Namenda XR - Price Per Unit & Supply Of 14mg & 28mg Extended Release Capsules (US$), August'2025
Figure 8-5: Namenda XR - Price Per Unit & Supply Of Extended Release Oral Kit (US$), August'2025
Figure 8-6: Generic Memantine - Price Per Unit & Supply Of 7mg & 21mg Extended Release Capsules (US$), August'2025
Figure 8-7: Generic Memantine - Price Per Unit & Supply Of 14mg Extended Release Capsules (US$), August'2025
Figure 8-8: Generic Memantine - Price Per Unit & Supply Of 28mg Extended Release Capsules (US$), August'2025
Figure 8-9: Razadyne ER - Price Per Unit & Supply (US$), August'2025
Figure 8-10: Generic Galantamine - Price Per Unit & Supply (US$), August'2025
Figure 9-1: Gocovri - Price Per Unit & Supply (US$), August'2025
Figure 9-2: Global - Gocovri Annual Sales (US$ Million), 2021-2025
Figure 9-3: Global - Gocovri Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 9-4: Global - Gocovri Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 9-5: Osmolex ER - Price Per Unit & Supply Of 322 mg Extended Release Tablet (US$), August'2025
Figure 9-6: Osmolex ER - Price Per Unit & Supply Of 129 mg Extended Release Tablet (US$), August'2025
Figure 9-7: Osmolex ER - Price Per Unit & Supply Of 193 mg Extended Release Tablet (US$), August'2025
Figure 9-8: Osmolex ER - Price Per Unit & Supply Of 258 mg Extended Release Tablet (US$), August'2025
Figure 9-9: Mirapex ER - Available Dosage Strengths (mg)
Figure 9-10: Mirapex ER - Price Per Unit & Supply Of 0.375 mg & 0.75 mg Extended Release Tablets (US$), August'2025
Figure 9-11: Mirapex ER - Price Per Unit & Supply Of 1.5 mg Extended Release Tablet (US$), August'2025
Figure 9-12: Mirapex ER - Price Per Unit & Supply Of 2.25 mg, 3 mg, 3.75 mg & 4.5 mg Extended Release Tablets (US$), August'2025
Figure 9-13: Generic Pramipexole - Price Per Unit & Supply Of 0.375 mg & 0.75 mg (US$), August'2025
Figure 9-14: Generic Pramipexole - Price Per Unit & Supply Of 1.5 mg, 2.25 mg, 3 mg, & 4.5 mg (US$), August'2025
Figure 9-15: Generic Pramipexole - Price Per Unit & Supply Of 3.75 mg (US$), August'2025
Figure 10-1: Invega - Available Dosage Strengths (mg)
Figure 10-2: Invega - Price Per Unit & Supply (US$), August'2025
Figure 10-3: Invega Sustenna - Price Per Unit & Supply (US$), August'2025
Figure 10-4: Invega Trinza - Price Per Unit & Supply (US$), August'2025
Figure 10-5: Invega Hafyera - Price Per Unit & Supply (US$), August'2025
Figure 10-6: Global - Invega Franchise Annual Sales (US$ Million), 2020-2025
Figure 10-7: Global - Invega Franchise Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 10-8: Global - Invega Franchise Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 10-9: US - Invega Franchise Annual Sales (US$ Million), 2020-2025
Figure 10-10: US - Invega Franchise Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 10-11: US - Invega Franchise Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 10-12: ROW - Invega Franchise Annual Sales (US$ Million), 2020-2025
Figure 10-13: ROW - Invega Franchise Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 10-14: ROW - Invega Franchise Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 10-15: Seroquel XR - Available Dosage Strengths (mg)
Figure 10-16: Seroquel XR - Price Per Unit & Supply (US$), August'2025
Figure 10-17: Generic Quetiapine - Price Per Unit & Supply Of 60 Tablets (US$), August'2025
Figure 10-18: Generic Quetiapine - Price Per Unit & Supply Of 100 Tablets (US$), August'2025
Figure 10-19: Global - Seroquel XR Total Annual Sales (US$ Million), 2020-2021
Figure 10-20: Abilify Maintena - Available Dosage Strengths (mg)
Figure 10-21: Abilify Maintena - Price Per Supply of Vial & Prefilled Syringe (US$), August'2025
Figure 10-22: Abilify Asimtufii - Price Per Unit & Supply (US$), August'2025
Figure 10-23: Global - Abilify Franchise Annual Sales (US$ Million), 2020-2025
Figure 10-24: Global - Abilify Franchise Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 10-25: Global - Abilify Franchise Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 10-26: Aristada - Available Dosage Strengths (mg)
Figure 10-27: Aristada - Price Per Unit & Supply (US$), August'2025
Figure 10-28: Aristada Initio - Price Per Unit & Supply (US$), August'2025
Figure 10-29: Global - Aristada Franchise Annual Sales (US$ Million), 2020-2025
Figure 10-30: Global - Aristada Franchise Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 10-31: Global - Aristada Franchise Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 10-32: Rykindo - Available Dosage Strengths (mg)
Figure 10-33: Rykindo - Price Per Supply (US$), August'2025
Figure 10-34: Generic Risperidone - Price Per Supply (US$), August'2025
Figure 10-35: Risperdal Consta - Price Per Supply (US$), August'2025
Figure 10-36: Global - Risperdal Consta Annual Sales (US$ Million), 2020-2021
Figure 10-37: Uzedy - Price Per Unit & Supply (US$), August'2025
Figure 11-1: Hysingla ER - Available Dosage Strengths (mg)
Figure 11-2: Hysingla ER - Price Per Unit & Supply (US$), August'2025
Figure 11-3: Generic Hydrocodone - Price Per Unit & Supply (US$), August'2025
Figure 11-4: Nucynta ER - Available Dosage Strengths (mg)
Figure 11-5: Nucynta ER - Price Per Unit & Supply (US$), August'2025
Figure 11-6: Global - Nucynta ER Annual Sales (US$ Million), 2020-2025
Figure 11-7: Global - Nucynta ER Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-8: Global - Nucynta ER Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-9: Kadian - Available Dosage Strengths (mg)
Figure 11-10: Kadian - Price Per Unit & Supply Of Strength 10 mg/12 hr (US$), August'2025
Figure 11-11: Kadian - Price Per Unit & Supply Of Strength 10 mg/12 to 24 hr & 10 mg/24 hr (US$), August'2025
Figure 11-12: Kadian - Price Per Unit & Supply Of Strength 20 mg/12 hr (US$), August'2025
Figure 11-13: Kadian - Price Per Unit & Supply Of Strength 20 mg/12 to 24 hr & 20 mg/24 hr (US$), August'2025
Figure 11-14: Kadian - Price Per Unit & Supply Of Strength 30 mg/12 hr (US$), August'2025
Figure 11-15: Kadian - Price Per Unit & Supply Of Strength 30 mg/12 to 24 hr & 30 mg/24 hr (US$), August'2025
Figure 11-16: Kadian - Price Per Unit & Supply Of Strength 40 mg/12 to 24 hr & 40 mg/24 hr (US$), August'2025
Figure 11-17: Kadian - Price Per Unit & Supply Of Strength 50 mg/12 hr (US$), August'2025
Figure 11-18: Kadian - Price Per Unit & Supply Of Strength 50 mg/12 to 24 hr & 50 mg/24 hr (US$), August'2025
Figure 11-19: Kadian - Price Per Unit & Supply Of Strength 60 mg/12 hr (US$), August'2025
Figure 11-20: Kadian - Price Per Unit & Supply Of Strength 60 mg/12 to 24 hr (US$), August'2025
Figure 11-21: Kadian - Price Per Unit & Supply Of Strength 60 mg/24 hr (US$), August'2025
Figure 11-22: Kadian - Price Per Unit & Supply Of Strength 70 mg/12 to 24 hr (US$), August'2025
Figure 11-23: Kadian - Price Per Unit & Supply Of Strength 80 mg/12 hr, 80 mg/12 to 24 hr & 80 mg/24 hr (US$), August'2025
Figure 11-24: Kadian - Price Per Unit & Supply Of Strength 100 mg/12 hr, 100 mg/12 to 24 hr & 100 mg/24 hr (US$), August'2025
Figure 11-25: Kadian - Price Per Unit & Supply Of Strength 130 mg/12 to 24 hr & 150 mg/12 to 24 hr (US$), August'2025
Figure 11-26: Kadian - Price Per Unit & Supply Of Strength 200 mg/12 to 24 hr & 200 mg/24 hr (US$), August'2025
Figure 11-27: Xtampza ER - Available Dosage Strengths (mg)
Figure 11-28: Xtampza ER - Price Per Unit & Supply (US$), August'2025
Figure 11-29: Global - Xtampza ER Annual Sales (US$ Million), 2020-2025
Figure 11-30: Global - Xtampza ER Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 11-31: Global - Xtampza ER Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 11-32: MS Contin - Available Dosage Strengths (mg)
Figure 11-33: MS Contin - Price Per Unit & Supply (US$), August'2025
Figure 11-34: Embeda - Price Per Unit & Supply (US$), August'2025
Figure 11-35: Zynrelef - Price Per Unit & Supply (US$), August'2025
Figure 11-36: Global - Zynrelef Annual Sales (US$ Million), 2021-2025
Figure 11-37: Global - Zynrelef Quarterly Sales (US$ Million), H1'2025
Figure 11-38: Global - Zynrelef Quarterly Sales (US$ Million), 2024
Figure 11-39: ConZip - Available Dosage Strengths (mg)
Figure 11-40: ConZip - Price Per Unit & Supply (US$), August'2025
Figure 11-41: Generic Hydromorphone - Available Dosage Strengths (mg)
Figure 11-42: Generic Hydromorphone - Price Per Unit & Supply (US$), August'2025
Figure 12-1: Ampyra - Price Per Unit & Supply (US$), August'2025
Figure 12-2: Generic Dalfampridine - Price Per Unit & Supply (US$), August'2025
Figure 12-3: ROW - Fampyra Annual Sales (US$ Million), 2020-2025
Figure 12-4: ROW - Fampyra Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 12-5: Tecfidera - Available Dosage Strengths (mg)
Figure 12-6: Tecfidera - Price Per Unit & Supply (US$), August'2025
Figure 12-7: Generic Dimethyl Fumarate - Price Per Unit & Supply (US$), August'2025
Figure 12-8: Global - Tecdifera Annual Sales (US$ Million), 2020-2025
Figure 12-9: Global - Tecdifera Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 12-10: Global - Tecdifera Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 12-11: US - Tecdifera Annual Sales (US$ Million), 2020-2025
Figure 12-12: US - Tecdifera Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 12-13: US - Tecdifera Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 12-14: ROW - Tecdifera Annual Sales (US$ Million), 2020-2025
Figure 12-15: ROW - Tecdifera Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 12-16: ROW - Tecdifera Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 12-17: Vumerity - Price Per Unit & Supply (US$), August'2025
Figure 12-18: Global - Vumerity Annual Sales (US$ Million), 2020-2025
Figure 12-19: Global - Vumerity Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 12-20: Global - Vumerity Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 12-21: US - Vumerity Annual Sales (US$ Million), 2020-2025
Figure 12-22: US - Vumerity Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 12-23: US - Vumerity Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 12-24: ROW - Vumerity Annual Sales (US$ Million), 2020-2025
Figure 12-25: ROW - Vumerity Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 12-26: ROW - Vumerity Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 12-27: Rayos - Available Dosage Strengths (mg)
Figure 12-28: Rayos - Price Per Unit & Supply (US$), August'2025
Figure 12-29: US - Rayos Annual Sales (US$ Million), 2020-2023
Figure 12-30: Global - Rayos Quarterly Sales (US$ Million), H1'2023
Figure 12-31: Bafiertam - Price Per Unit & Supply (US$), August'2025
Figure 13-1: Glumetza - Available Dosage Strengths (mg)
Figure 13-2: Glumetza - Price Per Unit & Supply (US$), August'2025
Figure 13-3: Generic Metformin - Price Per Unit & Supply Of 500mg (US$), August'2025
Figure 13-4: Generic Metformin - Price Per Unit & Supply Of 1000mg (US$), August'2025
Figure 13-5: Glucotrol XL - Available Dosage Strengths (mg)
Figure 13-6: Glucotrol XL - Price Per Unit & Supply Of Strength 5 mg (US$), August'2025
Figure 13-7: Glucotrol XL - Price Per Unit & Supply Of Strength 10 mg (US$), August'2025
Figure 13-8: Generic Glipizide - Price Per Unit & Supply Of Strength 5 mg (US$), August'2025
Figure 13-9: Generic Glipizide - Price Per Unit & Supply Of Strength 10 mg (US$), August'2025
Figure 13-10: Glucophage XR - Available Dosage Strengths (mg)
Figure 13-11: Glucophage XR - Price Per Unit & Supply Of Strength 10 mg (US$), August'2025
Figure 13-12: Glucophage XR - Price Per Unit & Supply Of Strength 750 mg (US$), August'2025
Figure 13-13: Trijardy XR - Price Per Unit & Supply Of Strengths 10 mg-5 mg-1000 mg & 25 mg-5 mg-1000 mg (US$), August'2025
Figure 13-14: Trijardy XR - Price Per Unit & Supply Of Strengths 10 mg-5 mg-1000 mg & 25 mg-5 mg-1000 mg (US$), August'2025
Figure 13-15: Synjardy XR - Price Per Unit & Supply Of 10 mg-1000 mg & 25 mg-1000 mg (US$), August'2025
Figure 13-16: Synjardy XR - Price Per Unit & Supply Of 5 mg-1000 mg & 12.5 mg-1000 mg (US$), August'2025
Figure 14-1: Procardia XL - Available Dosage Strengths (mg)
Figure 14-2: Procardia XL - Price Per Unit & Supply Of 100 Tablets (US$), August'2025
Figure 14-3: Procardia XL - Price Per Unit & Supply Of 300 Tablets (US$), August'2025
Figure 14-4: Toprol XL - Available Dosage Strengths
Figure 14-5: Toprol XL - Price Per Unit & Supply Of Strengths 25 mg, 50 mg & 200 mg (US$), August'2025
Figure 14-6: Toprol XL - Price Per Unit & Supply Of Strengths 100 mg (US$), August'2025
Figure 14-7: Global - Toprol XL Annual Sales (US$ Million), 2020-2024
Figure 14-8: Global - Toprol XL Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 14-9: US - Toprol XL Annual Sales (US$ Million), 2020-2024
Figure 14-10: EU - Toprol XL Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 14-11: EU - Toprol XL Annual Sales (US$ Million), 2020-2024
Figure 14-12: EU - Toprol XL Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 14-13: ROW - Toprol XL Annual Sales (US$ Million), 2020-2024
Figure 14-14: ROW - Toprol XL Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 14-15: Verelan PM - Available Dosage Strengths (mg)
Figure 14-16: Verelan PM - Price Per Unit & Supply (US$), August'2025
Figure 14-17: Generic Verapamil - Price Per Unit & Supply (US$), August'2025
Figure 14-18: Cardizem LA - Available Dosage Strengths (mg)
Figure 14-19: Cardizem LA - Price Per Unit & Supply Of 30 Tablets (US$), August'2025
Figure 14-20: Cardizem LA - Price Per Unit & Supply Of 90 Tablets (US$), August'2025
Figure 14-21: Calan SR - Available Dosage Strengths (mg)
Figure 14-22: Calan SR - Price Per Unit & Supply Of 120 mg & 180 mg (US$), August'2025
Figure 14-23: Calan SR - Price Per Unit & Supply Of 240 mg (US$), August'2025
Figure 14-24: Altoprev - Available Dosage Strengths (mg)
Figure 14-25: Altoprev - Price Per Unit & Supply (US$), August'2025
Figure 14-26: Cardura XL - Available Dosage Strengths (mg)
Figure 14-27: Cardura XL - Price Per Unit & Supply (US$), August'2025
Figure 15-1: Apretude - Price Per Unit & Supply (US$), August'2025
Figure 15-2: Cabenuva - Price Per Unit & Supply (US$), August'2025
Figure 15-3: Rukobia - Price Per Unit & Supply (US$), August'2025
Figure 16-1: Qelbree - Price Per Unit & Supply Of Strengths 100 mg & 150 mg (US$), August'2025
Figure 16-2: Qelbree - Price Per Unit & Supply Of Strength 200 mg (US$), August'2025
Figure 16-3: Global - Qelbree Annual Sales (US$ Million), 2021-2023
Figure 16-4: Global - Qelbree Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 16-5: Global - Qelbree Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 16-6: Jornay PM - Available Dosage Strengths (mg)
Figure 16-7: Jornay PM - Price Per Unit & Supply (US$), August'2025
Figure 16-8: Global - Jornay PM Annual Sales (US$ Million), 2024-2025
Figure 16-9: Global - Jornay PM Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 16-10: Global - Jornay PM Quarterly Sales (US$ Million), Q3-Q4'2024
Figure 16-11: Cotempla XR-ODT - Available Dosage Strengths (mg)
Figure 16-12: Cotempla XR-ODT - Price Per Unit & Supply (US$), August'2025
Figure 16-13: Adzenys XR-ODT - Available Dosage Strengths (mg)
Figure 16-14: Adzenys XR-ODT - Price Per Unit & Supply (US$), August'2025
Figure 16-15: Global - Adzenys XR-ODT & Cotempla XR-ODT Annual Sales (US$ Million), 2021-2025
Figure 16-16: Global - Adzenys XR-ODT & Cotempla XR-ODT Quarterly Sales (US$ Million), Q1'2025
Figure 16-17: Global - Adzenys XR-ODT & Cotempla XR-ODT Quarterly Sales (US$ Million), Q1-Q4'2025
Figure 16-18: Intuniv - Available Dosage Strengths (mg)
Figure 16-19: Intuniv - Price Per Unit & Supply (US$), August'2025
Figure 16-20: Global - Intuniv Annual Sales (US$ Million), 2020-2025
Figure 16-21: Global - Intuniv Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 16-22: Focalin XR - Available Dosage Strengths (mg)
Figure 16-23: Focalin XR - Price Per Unit & Supply (US$), August'2025
Figure 17-1: Rinvoq - Available Dosage Strengths (mg)
Figure 17-2: Rinvoq - Price Per Unit & Supply (US$), August'2025
Figure 17-3: Global - Rinvoq Annual Sales (US$ Million), 2020-2025
Figure 17-4: Global - Rinvoq Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 17-5: Global - Rinvoq Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 17-6: US - Rinvoq Annual Sales (US$ Million), 2020-2025
Figure 17-7: US - Rinvoq Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 17-8: US - Rinvoq Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 17-9: ROW - Rinvoq Annual Sales (US$ Million), 2020-2025
Figure 17-10: ROW - Rinvoq Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 17-11: ROW - Rinvoq Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 17-12: Ortikos - Available Dosage Strengths (mg)
Figure 17-13: Ortikos - Price Per Unit & Supply (US$), August'2025
Figure 17-14: Xeljanz XR - Available Dosage Strengths (mg)
Figure 17-15: Xeljanz XR - Price Per Unit & Supply (US$), August'2025
Figure 17-16: Global - Xeljanz XR Annual Sales (US$ Million), 2020-2025
Figure 17-17: Global - Xeljanz XR Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 17-18: Global - Xeljanz XR Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 17-19: US - Xeljanz XR Annual Sales (US$ Million), 2020-2025
Figure 17-20: US - Xeljanz XR Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 17-21: US - Xeljanz XR Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 17-22: ROW - Xeljanz XR Annual Sales (US$ Million), 2020-2025
Figure 17-23: ROW - Xeljanz XR Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 17-24: ROW - Xeljanz XR Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 17-25: Mestinon Timespan - Price Per Unit & Supply (US$), August'2025
Figure 17-26: Generic Pyridostigmine - Price Per Unit & Supply (US$), August'2025
Figure 17-27: Symax Duotab - Price Per Unit & Supply (US$), August'2025
Figure 18-1: Aemcolo - Price Per Unit & Supply (US$), August'2025
Figure 18-2: Talicia - Price Per Unit & Supply (US$), August'2025
Figure 19-1: Sublocade - Price Per Unit & Supply (US$), August'2025
Figure 19-2: Global - Sublocade Annual Sales (US$ Million), 2020-2025
Figure 19-3: Global - Sublocade Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 19-4: Global - Sublocade Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 19-5: Sublocade - Price Per Unit & Supply Of Strength 50 mg/mL (US$), August'2025
Figure 19-6: Sublocade - Price Per Unit & Supply Of Strength 355.6 mg/mL (US$), August'2025
Figure 20-1: Astagraf XL - Available Dosage Strengths (mg)
Figure 20-2: Astagraf XL - Price per Unit & Supply (US$), August'2025
Figure 20-3: Envarsus XR - Available Dosage Strengths (mg)
Figure 20-4: Envarsus XR - Price per Unit & Supply Of 30 Tablets (US$), August'2025
Figure 20-5: Envarsus XR - Price per Unit & Supply Of 100 Tablets (US$), August'2025
Figure 21-1: Trokendi XR - Available Dosage Strengths (mg)
Figure 21-2: Trokendi XR - Price per Unit & Supply (US$), August'2025
Figure 21-3: Global - Trokendi XR Annual Sales (US$ Million), 2020-2025
Figure 21-4: Global - Trokendi XR Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 21-5: Global - Trokendi XR Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 21-6: Global - Oxtellar XR Annual Sales (US$ Million), 2020-2025
Figure 21-7: Global - Oxtellar XR Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 21-8: Global - Oxtellar XR Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 21-9: Keppra XR - Available Dosage Strengths (mg)
Figure 21-10: Keppra XR - Price per Unit & Supply (US$), August'2025
Figure 21-11: Generic levetiracetam - Price per Unit & Supply Of 500 mg (US$), August'2025
Figure 21-12: Keppra XR - Price per Unit & Supply (US$), August'2025
Figure 21-13: Global - Oxtellar XR Annual Sales (US$ Million), 2020-2025
Figure 21-14: Roweepra XR - Available Dosage Strengths (mg)
Figure 21-15: Roweepra XR - Price per Unit & Supply (US$), August'2025
Figure 21-16: Depakote - Available Dosage Strengths (mg)
Figure 21-17: Depakote - Price per Unit & Supply (US$), August'2025
Figure 21-18: Depakote ER - Available Dosage Strengths (mg)
Figure 21-19: Depakote ER - Price per Unit & Supply (US$), August'2025
Figure 21-20: Depakote Sprinkles - Price per Unit & Supply (US$), August'2025
Figure 22-1: Effexor XR - Available Dosage Strengths (mg)
Figure 22-2: Effexor XR - Price per Unit & Supply Of 30 Capsules (US$), August'2025
Figure 22-3: Effexor XR - Price per Unit & Supply Of 90 Capsules (US$), August'2025
Figure 22-4: Generic Venlafaxine - Price per Unit & Supply Of 37.5 mg (US$), August'2025
Figure 22-5: Generic Venlafaxine - Price per Unit & Supply Of 37.5 mg (US$), August'2025
Figure 22-6: Generic Venlafaxine - Price per Unit & Supply Of 37.5 mg (US$), August'2025
Figure 22-7: Global - Effexor XR Annual Sales (US$ Million), 201-2025
Figure 22-8: Global - Effexor XR Quarterly Sales (US$ Million), Q1 & Q2'2025
Figure 22-9: Global - Effexor XR Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 22-10: Xanax XR - Available Dosage Strengths (mg)
Figure 22-11: Xanax XR - Price per Unit & Supply (US$), August'2025
Figure 22-12: Generic Alprazolam - Price per Unit & Supply (US$), August'2025
Figure 22-13: Ambien CR - Available Dosage Strengths (mg)
Figure 22-14: Ambien CR - Price per Unit & Supply (US$), August'2025
Figure 22-15: Generic Zolpidem - Price per Unit & Supply Of 6.25 mg (US$), August'2025
Figure 22-16: Generic Zolpidem - Price per Unit & Supply Of 12.5 mg (US$), August'2025
Figure 23-1: Klor-Con 8 - Price per Unit & Supply (US$), August'2025
Figure 23-2: Generic Potassium Chloride - Price per Unit & Supply Of 8 mEq (US$), August'2025
Figure 23-3: Klor-Con 10 - Price per Unit & Supply (US$), August'2025
Figure 23-4: Klor-Con M10 - Price per Unit & Supply (US$), August'2025
Figure 23-5: Klor-Con M15 - Price per Unit & Supply (US$), August'2025
Figure 23-6: Generic Potassium Chloride - Price per Unit & Supply Of 15 mEq (US$), August'2025
Figure 23-7: Klor-Con M20 - Price per Unit & Supply (US$), August'2025
Figure 24-1: Controlled Drug Delivery System Market - Key Drivers
Figure 24-2: Controlled Drug Delivery System Market - Major Challenges

List of Tables

Table 1-1: Conventional vs. Novel Drug Delivery
Table 1-2: Sustained vs. Controlled Release
Table 5-1: Controlled Release Drugs - Recent US FDA Approvals

Global Controlled Release Drug Delivery Market, Drug Dosage, Price, Sales & Clinical Trials Insight 2030

Description

Table of Contents

List of Tables

Table of Contents

1. Introduction To Controlled Drug Delivery

2. Material Based Approaches For Controlled Drug Delivery

3. Global Controlled Release Drug Delivery Market Trends

4. Controlled Drug Delivery Research & Clinical Trends By Indication

5. Global Controlled Release Drug Market Trends By Region

6. Global Controlled Release Drugs Clinical Pipeline By Company, Indication & Phase

7. Marketed Controlled Release Drugs Clinical Insight By Company, Country & Indication

8. Controlled Release Drugs for Alzheimer's Disease - Pricing & Dosage Insight

9. Controlled Release Drugs for Parkinson's Disease - Pricing & Dosage Insight

10. Controlled Release Drugs for Schizophrenia - Pricing & Dosage Insight

11. Controlled Release Drugs for Chronic & Post-Operative Pain - Pricing & Dosage Insight

12. Controlled Release Drugs for Multiple Sclerosis - Pricing & Dosage Insight

13. Controlled Release Drugs for Diabetes Mellitus Type II - Pricing & Dosage Insight

14. Controlled Release Drugs for Cardiovascular Diseases - Pricing & Dosage Insight

15. Controlled Release Drugs for HIV - Pricing & Dosage Insight

16. Controlled Release Drugs for Attention Deficit Hyperactivity Disorder - Pricing & Dosage Insight

17. Controlled Release Drugs for Inflammatory & Autoimmune Diseases - Pricing & Dosage Insight

18. Controlled Release Drugs for Bacterial Infections - Pricing & Dosage Insight

19. Controlled Release Drugs for Opioid Use Disorder - Pricing & Dosage Insight

20. Controlled Release Drugs for Preventing Organ Transplant Rejection - Pricing & Dosage Insight

21. Controlled Release Drugs for Migraine & Seizure - Pricing & Dosage Insight

22. Controlled Release Drugs for Mental Health and Sleep Disorders - Pricing & Dosage Insight

23. Controlled Release Drugs for Metabolic and Electrolyte Disorders - Pricing & Dosage Insight

24. Global Controlled Drug Delivery System Market Dynamics

25. Competitive Landscape

List of Figures

List of Tables